Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced the start of a Phase Ib biomarker study of the effect of AUT00206, a first-in-class Kv3 ion channel modulator, on patients with schizophrenia.
The clinical trial is being conducted in collaboration with King’s College London, with Professor Oliver Howes as Principal Investigator. It is designed to test the safety, tolerability and pharmacokinetics of AUT00206 in patients with schizophrenia, and also explores the effects of AUT00206 on relevant central biomarkers.
Twenty-four patients, diagnosed with schizophrenia within the last five years, will receive AUT00206 or placebo for 28 days. During that period, electrophysiological measures of central nervous function known to be impaired in schizophrenia will be investigated for signs of improvement. The subjects will also undergo brain imaging, tests of cognition and tests of auditory function, in addition to routine safety monitoring. Because of the pioneering and novel mechanism of action of this drug, a key objective is to characterise this range of biomarkers which will inform the future development of the drug.
To talk to the company about joining the trial (only in the UK I believe)
Contact: Anil Sajjala email@example.com
More on the clinical trial here:
More company information here: